Email updates

Keep up to date with the latest news and content from Experimental Hematology and Oncology and BioMed Central.

Open Access Letter to the Editor

Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia

Klára Gadó1*, András Matolcsy2, Judit Csomor2, Dóra Kicsi3, Csaba Bödör2 and Gyula Domján1

Author Affiliations

1 1st Department of Internal Medicine, Semmelweis University, Korányi S. Street 2, 1083, Budapest, Hungary

2 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary

3 Department of Internal Medicine, St Rokus Hospital, Budapest, Hungary

For all author emails, please log on.

Experimental Hematology & Oncology 2012, 1:17  doi:10.1186/2162-3619-1-17

Published: 11 July 2012

Abstract

Tyrosine kinase inhibitors specific for BCR-ABL, were a major breakthrough in CML therapy. Second generation tyrosine kinase inhibitors (dasatinib, nilotinib) are indicated for imatinib resistant and intolerant patients. Present guidelines recommend continuous drug dosing for maintaining remission. There is no available data concerning the optimal duration of dasatinib therapy. We report the case of an imatinib intolerant patient who succeeded a complete molecular remission with dasatinib. Dasatinib was stopped bacause of intolerance, but complete molecular remission was sustained for one year and minor molecular remission for 27 months after discontinuation of dasatinib.

Keywords:
Chronic myeloid leukemia; Dasatinib; Imatinib; Tyrosine kinase inhibitor; Drug intolerance